Oncogenes and tumor suppressor genes
- PMID: 20719876
- PMCID: PMC2944361
- DOI: 10.1101/cshperspect.a003236
Oncogenes and tumor suppressor genes
Abstract
Breast cancer progression involves multiple genetic events, which can activate dominant-acting oncogenes and disrupt the function of specific tumor suppressor genes. This article describes several key oncogene and tumor suppressor signaling networks that have been implicated in breast cancer progression. Among the tumor suppressors, the article emphasizes BRCA1/2 and p53 tumor suppressors. In addition to these well characterized tumor suppressors, the article highlights the importance of PTEN tumor suppressor in counteracting PI3K signaling from activated oncogenes such as ErbB2. This article discusses the use of mouse models of human breast that recapitulate the key genetic events involved in the initiation and progression of breast cancer. Finally, the therapeutic potential of targeting these key tumor suppressor and oncogene signaling networks is discussed.
Similar articles
-
Analysis of oncogenes and tumor suppressor genes in human breast cancer.Jpn J Cancer Res. 1993 Aug;84(8):871-8. doi: 10.1111/j.1349-7006.1993.tb02060.x. Jpn J Cancer Res. 1993. PMID: 8104920 Free PMC article.
-
[Oncogene and tumor suppressor gene].Nihon Rinsho. 2000 Apr;58 Suppl:25-9. Nihon Rinsho. 2000. PMID: 11025969 Review. Japanese. No abstract available.
-
Activated oncogenes and putative tumor suppressor genes involved in human breast cancers.Cancer Treat Res. 1992;63:15-60. doi: 10.1007/978-1-4615-3088-6_2. Cancer Treat Res. 1992. PMID: 1363356 Review.
-
Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).Int J Oncol. 2000 Mar;16(3):567-76. doi: 10.3892/ijo.16.3.567. Int J Oncol. 2000. PMID: 10675491 Review.
-
[Oncogenes and suppressor genes in the genesis and progression of solid tumors in children].Pediatr Med Chir. 1994 May-Jun;16(3):203-9. Pediatr Med Chir. 1994. PMID: 7971441 Review. Italian.
Cited by
-
Emerging Gene-editing nano-therapeutics for Cancer.Heliyon. 2024 Oct 20;10(21):e39323. doi: 10.1016/j.heliyon.2024.e39323. eCollection 2024 Nov 15. Heliyon. 2024. PMID: 39524822 Free PMC article. Review.
-
Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis.Med Oncol. 2024 Oct 1;41(11):254. doi: 10.1007/s12032-024-02524-0. Med Oncol. 2024. PMID: 39352464 Review.
-
Targeting cellular plasticity: esculetin-driven reversion of stem cell-like characteristics and EMT phenotype in transforming cells with sequential p53/p73 knockdowns.BMC Cancer. 2024 Sep 19;24(1):1164. doi: 10.1186/s12885-024-12736-2. BMC Cancer. 2024. PMID: 39300412 Free PMC article.
-
Transcription factor ZEB1 coordinating with NuRD complex to promote oncogenesis through glycolysis in colorectal cancer.Front Pharmacol. 2024 Aug 13;15:1435269. doi: 10.3389/fphar.2024.1435269. eCollection 2024. Front Pharmacol. 2024. PMID: 39193340 Free PMC article.
-
Cytoplasmic Expression of the EGFL6 Protein Is an Independent Prognostic Factor for Shortened Patient Survival in Human Hepatocellular Carcinoma.In Vivo. 2024 Sep-Oct;38(5):2455-2463. doi: 10.21873/invivo.13715. In Vivo. 2024. PMID: 39187367 Free PMC article.
References
-
- Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI 2002. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 21: 198–206 - PubMed
-
- Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL 1992. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974–979 - PubMed
-
- Andrechek ER, White D, Muller WJ 2005. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 24: 932–937 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous